| [1] |
Armstrong AE, Belzberg AJ, Crawford JR. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas[J].BMC Cancer, 2023, 23(1): 553-559.
|
| [2] |
Demir U . Evaluation of Ocular Findings in Pediatric Patients With Neurofibromatosis Type 1[J].Child Neurol. 2025, 41(3): 396-402.
|
| [3] |
梁小芳. 神经纤维瘤病1型患者的眼部特征分析[J]. 眼科，2023，5：421-424.
|
| [4] |
Tabata MM, Li S, Knight P, et al. Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry[J]. JCI Insight, 2020, 5(16): e136262-e136269.
|
| [5] |
中华医学会整形分会神经纤维瘤病学组. 丛状神经纤维瘤的全病程管理专家共识(2025版)[J].中华医学杂志.2025，105(5)：331-345.
|
| [6] |
Choi E, Lee J, Kim H. TGF-B superfamily-induced transcriptional activation pathways establish the RAD52-dependent ALT machinery during malignant transformation of MPNSTs[J]. Sci Rep, 2024, 14(1): 26475-264782.
|
| [7] |
Copley-Merriman C, Yang Xiaoqin. Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review[J]. Adolesc Health Med Ther, 2021, 12: 55-66.
|
| [8] |
张雷.Ⅰ型神经纤维瘤病相关肿瘤的诊疗进展[J].中华神经外科疾病研究杂志，2025，19(3)：150-155.
|
| [9] |
Kotch C, Avery R, Getz KD. Risk factors for treatment re-fractory and relapsed opticpathwayglioma inchildrenwith neurofibro-matosis type 1[J].Neuro Oncol, 2022, 24(8): 1377-1386.
|
| [10] |
Mahdi J, Goyal MS, Griffith J. Nonoptic pathway tumors in children with neurofibromatosis type I[J].Neurology, 2020, 95(8): e1052-1059.
|
| [11] |
Jiramongkolchai P, Schwartz MS, Friedman RA. Management of neurofibromatosis type 2-associated vestibular schwannomas[J].Otolaryngol Clin N Am, 2023, 56: 533-541.
|
| [12] |
Li Qian, Liu Guiqin. Neurofibromatosis type 2 misdiagnosed as amblyopia-a case report and literature review[J].Front Med (Lausanne), 2025, 12: 1556494.
|
| [13] |
李倩. 首诊眼科的4例2型神经纤维瘤病眼部病变特征[J]. 眼科学报，2025，40(8)：595-600.
|
| [14] |
中华人民共和国国家卫生健康委员会. 神经纤维瘤病诊疗指南(2025版)[J].中国修复重建外科杂志，2026，40(1)：153-160.
|
| [15] |
Moualed D, Wong J, Thomas O. Prevalkence and natural historyof schwannomas in neurohbromatosis type2(NF2)：the influence ofpathogenis variants[J]. Eur J Hum Gemet, 2022, 30(4): 458464.
|
| [16] |
Pranjal R, Girish B．Classification of schwannomas and the new naming convention for " neurofibromatosis-2" ：Genetic updates and international consensus recommendation[J]. Neuroradiol J, 2025, 38(5): 533-542.
|
| [17] |
Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation[J].Genet Med, 2021, 23(8): 1506-1513.
|
| [18] |
中国罕见病联盟.Ⅰ型神经纤维瘤病多学科诊疗协作组．I型神经纤维瘤病多学科指南(2023版)[J]. 罕见病研究，2023，2(2)：210-230.
|
| [19] |
祝思涵. 儿童视路胶质瘤诊断、治疗和预后观察的研究进展[J]. 国际神经病学神经外科学杂志，2020，47(2)：196-199.
|
| [20] |
Abolhasan E, Sara H, Zohreh H. Optic pathway glio mas: clinical manifestation，treatment，and follow up[J]. Pediatr Neurosurg, 2016, 51(5): 223-228.
|
| [21] |
Gaonker CH, Mukherjee AK, Pokle M. Involvement of the eye and orbit in neurofibromatosis type 1[J]. Indian JOphthalmol, 1992, 40(1): 2-4.
|
| [22] |
Barnett C, Alon T, Abraham A. Evidence of smallfiber neuropathy in neurofibromatosis type 1[J]. Muscle Nerve, 2019, 60(6): 673-678.
|
| [23] |
Ghahvehchian H, Latifi G, Fard MA. Quantitative assessment of the corneal subbasal nerve plexus in children with neurofibromatosis type 1 and optic pathway glioma using in vivo confocal microscopy[J]. Sci Rep, 2025, 15: 42621.
|
| [24] |
Alabduljabbar M, Strianese D. The clinico pathologic profile of primary and recurrent orbital/periorbital plexiform neurofibromas (OPPN)[J]. PLoS One, 2021, 16(10): e0258802.
|
| [25] |
Avery RA, Katowitz JA, Fisher MJ, et al. Orbital periorbital plexiform neurofibromas in children with neurofibromatosis type 1：multidisciplinary recommendations for care[J]. Ophthalmology, 2017, 124(1): 123-132.
|
| [26] |
Chaudhry I, Morales J, Shamsi F, et al. Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome[J]. Eye, 2012, 26(4): 583.
|
| [27] |
张裕琳. 眼眶神经纤维瘤病I型相关斜视1例[J]. 中国眼耳鼻喉杂志，2025，25(S1)：34-37.
|
| [28] |
孙莉. 34例儿童I型神经纤维瘤病的眼底表现及临床分析[J]. 中国斜视与小儿眼科杂志，2025，33(1)：52-52.
|
| [29] |
舒婉婷. 儿童Ⅰ型神经纤维瘤病伴角膜缘神经纤维瘤继发性青光眼1例[J]. 中国眼耳鼻喉科杂志，2025，25(6)：548-511.
|
| [30] |
Chaudhary K, Dubey S. Optic Nerve Glioma，Plexiform Neurofibroma, and Secondary Glaucoma in a Child With a Rare NF1Variant (p.Gln83Ter): A Case Report [J]. Cureus, 2025, 17(11): e95957.
|
| [31] |
Ahmadova N, Kayaba M. Multimodal Imaging Characteristics and Diagnostic Value of Choroidal Nodules in Patients with Neurofibromatosis Type 1[J]. Turk J Ophthalmol, 2024, 54(3): 140-148.
|
| [32] |
冯云. 神经纤维瘤病累及眼部临床表现[J]. 国际眼科纵览，2024，48(2)：156-161.
|
| [33] |
Mallone F, Alisi L, Lucchino L. Insights into novel cho roidal and retinal clinical signs in neurofibromatosis type 1[J]. Int J Mol Sci, 2023, 24(17): 13481.
|
| [34] |
Abdolrahimzadeh S, Felli L, Plateroti R. Morphologic and vasculature features of the choroid and associated choroid-retinal thickness alterations in neurofibromatosis type 1[J]. Br J Ophthalmol, 2015, 99(6): 789-793.
|
| [35] |
Vagge A, Camicione P, Capris C. Choroidal abnormalities in neurofibromatosis type 1 detected by near-infrared reflectance imaging in paediatric population[J/OL]. ActaOphthalmol, 2015, 93(8): e667-e671.
|
| [36] |
TouzéR, Abitbol MM, Bremond-Gignac D. Function of the Retinal Pigment Epithelium in Patients With Neurofibromatosis Type 1[J].Invest Ophthalmol Vis Sci, 2022, 63(4): 6.
|
| [37] |
Moramarco A, Mallone F, Sacchetti M, et al. Hyperpigmented spots at fundus examination: a new ocular sign in Neurofibromatosis Type 1[J]. Orphanet J Rare Dis, 2021, 16(1): 147.
|
| [38] |
Wang GM, Thuente D, Bohnsack BL. Angle closure glaucoma in congenital ectropion uvea[J]. Am J Ophthalmol Case Rep, 2018, 10: 215-220.
|
| [39] |
Edward DP, Morales J, Bouhenni RA. Congenital ectropion uvea and mechanisms of glaucoma in neurofibromatpsis type1：newinsights[J]. Ophthalmolmgy, 2012, 119(7): 1485-1494.
|
| [40] |
Touzé R, Abitbol MM, Bremond-Gignac D, et al. Retinal vascular abnormalities in children with neurofibromatosis type 1[J]. Retina, 2021, 41: 2589-2595.
|
| [41] |
Zeydanl ÖE.Neurofibromatosis Type 1 Vasculopathy Presenting as Branch Retinal Vein Occlusion: Case Report and Review of the Literature Turk[J].Ophthalmol, 2023, 53(6): 390-394.
|
| [42] |
Koger AM, Atesoglu H, Yilmaz A. Quantitative OCT angi ography of the retinal and choroidal vascular circulation in pediat ric patients with neurofibromatosis type 1[J]. Aapos, 2022, 26 (4) ：189-189.
|
| [43] |
Somatilaka BN, Sadek A, McKay RM. Malignant Peripheral Nerve Sheath Tumor: Models, Biology, and Translation[J].Oncogene, 2022, 41(17): 2405-2421.
|
| [44] |
Armstrong AE, Belzberg AJ, Crawford JR, et al. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas[J].BMC Cancer, 2023, 23(1): 553.
|